Research article · 6 Oct 2026
Conference abstractPublished 14 Jul 2014
siRNAs- Are they a viable therapeutic approach for eye diseases?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The platforms currently employed in the treatment of retinal diseases include small molecules such as fluocinoloneacetonide (Retisert®) anddexamethasone (Ozurdex®), and large molecular entities such as aptamers (Macugen®), Fabs (Lucentis®), and Mabs (off label Avastin®). Other therapeutic approaches such as siRNAs, gene therapy, and nanomedicine, have been examined in ophthalmic clinical trials. In the context of delivery of therapeutics with sustained exposure to intraocular tissues, molecules like siRNAs or approaches such as gene delivery would appear to be optimal platforms, especially for targeting retinal neurons, which are non-mitotic cells. However, significant challenges have been encountered, and the horizon for therapeutic success seems cloudy due to the many clinical trial failures. This talk will discuss recent victories and challenges in gene silencing (siRNA?s) and gene delivery (AAV) and highlight potential strategies for future success.
Subjects
Ophthalmology & OptometryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Experimental Ophthalmology.
Short communication · 30 Aug 2026
Vision Science in the Modern Era: Integrating Neuroscience, Genetics, and Technology
Commentary · 3 Aug 2026
Emerging Frontiers in Experimental Ophthalmology: Innovations and Translational Challenges
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Experimental Ophthalmology
- SubjectOphthalmology & Optometry
- BylineArticles whose byline prints “Kay D. Rittenhouse”
